mTOR inhibitors: all 1,276 studies that test it

Page 13 of 13. Open to participants first (126), then studies with results posted, then the rest; newest registration first within each.

• Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft RecipientsCompletedNCT00261820Phase 4
• Everolimus in Treating Patients WIth Recurrent or Metastatic Breast CancerCompletedNCT00255788Phase 2
• Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00255658Phase 1
• Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant RecipientsCompletedNCT00254709Phase 4
• RAD001 Plus Docetaxel in Patients With Metastatic Breast CancerTerminatedNCT00253318Phase 1
• Use of Sirolimus vs. Tacrolimus For African-American Renal Transplant RecipientsStatus unknownNCT00252655Phase 4
• Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking SirolimusCompletedNCT00248313Phase 3
• Rapamycin vs Methotrexate in Diffuse SScCompletedNCT00241189Phase 1/2
• An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer PatientsCompletedNCT00235794Not applicable
• Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia PatientsCompletedNCT00235560Phase 2
• Study Evaluating CCI-779 in Relapsing Multiple SclerosisCompletedNCT00228397Phase 2
• Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant RecipientsCompletedNCT00204321Phase 4
• Study Evaluating Sirolimus in Kidney Transplant Recipients in IndiaCompletedNCT00195481Phase 4
• Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney TransplantCompletedNCT00188955Phase 4
• Everolimus for Treating Pediatric Patients With Recurrent or Refractory TumorsCompletedNCT00187174Phase 1
• Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant RecipientsCompletedNCT00170885Phase 4
• Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant RecipientsCompletedNCT00170859Phase 4
• Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant PatientsCompletedNCT00170833Phase 3
• Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free RegimenCompletedNCT00170820Phase 4
• Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.CompletedNCT00170794Phase 3
• Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no SteroidsCompletedNCT00170053Phase 1
• Study Evaluating Sirolimus in Kidney Transplant Recipients.CompletedNCT00167947Phase 3
• Sirolimus Blood Concentrations on Conversion From Oral Solution to TabletsStatus unknownNCT00166842Phase 4
• The Effect of Sirolimus on the Pharmacokinetics of TacrolimusStatus unknownNCT00166829Phase 4
• The Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant PatientsStatus unknownNCT00166816Phase 4
• Efficacy and Safety of Everolimus in de Novo Heart Transplant RecipientsCompletedNCT00150046Phase 3
• Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell TransplantationCompletedNCT00146614Phase 2
• Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationCompletedNCT00144703Phase 2
• Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
• Efficacy and Safety of Sirolimus in Combination With TacrolimusStatus unknownNCT00141804Phase 3
• Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant RecipientsTerminatedNCT00137345Phase 3
• TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant RecipientsCompletedNCT00133887Phase 3
• Study of Unrelated Cord Blood Transplantation Using Tacrolimus and SirolimusCompletedNCT00133367Phase 2
• Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT00124280Phase 2
• Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and EverolimusTerminatedNCT00117702Phase 2/3
• Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00112476Phase 1
• Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal WomenCompletedNCT00107016Phase 2
• Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00101088Phase 1
• Everolimus in Treating Patients With Stage IV MelanomaCompletedNCT00098553Phase 2
• CCI-779 and EKB-569 in Treating Patients With Advanced Solid TumorsCompletedNCT00098501Phase 1
• Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung CancerWithdrawnNCT00098462Phase 1/2
• Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant PatientsCompletedNCT00098241Phase 3
• A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) PatientsCompletedNCT00098007Phase 3
• Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft VasculopathyCompletedNCT00097968Phase 3
• Treating Multiple Sclerosis With Sirolimus, an Immune System SuppressorTerminatedNCT00095329Phase 1/2
• Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib MesylateCompletedNCT00093639Phase 1/2
• Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityActive, not recruitingNCT00092222Phase 2
• Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00089037Phase 1/2
• CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal TumorCompletedNCT00087074Phase 2
• CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT00086840Phase 2
• CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic PhaseCompletedNCT00084916Phase 2
• Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast CancerTerminatedNCT00083993Phase 3
• RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell LymphomaCompletedNCT00081874Phase 1/2
• Temsirolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00079456Phase 2
• CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung CancerCompletedNCT00079235Phase 2
• Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate TherapyTerminatedNCT00076206Phase 2
• CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00075647Phase 2
• Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of RelapseCompletedNCT00071968Phase 2
• Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's LymphomaTerminatedNCT00068302Phase 1
• Improving Immunosuppressive Treatment for Patients With Severe Aplastic AnemiaCompletedNCT00061360Phase 2
• Sirolimus Therapy for Idiopathic and Lupus Membranous NephropathyCompletedNCT00050713Phase 2
• Sirolimus in Treating Patients With Glioblastoma MultiformeCompletedNCT00047073Phase 1/2
• Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant RecipientsCompletedNCT00044720Phase 4
• Sirolimus for Focal Segmental GlomerulosclerosisCompletedNCT00040508Phase 2
• Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant RecipientsCompletedNCT00037531Phase 3
• CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's LymphomaCompletedNCT00033267Phase 2
• CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00028028Phase 2
• Steroid Withdrawal in Pediatric Kidney Transplant RecipientsTerminatedNCT00023244Phase 2
• Pediatric Kidney Transplant Without Calcineurin InhibitorsCompletedNCT00023231Not applicable
• CCI-779 in Treating Patients With Malignant GliomaCompletedNCT00022724Phase 1/2
• CCI-779 in Treating Patients With Metastatic MelanomaCompletedNCT00022464Phase 2
• CCI-779 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00016328Phase 2
• CCI-779 in Treating Patients With Prostate CancerCompletedNCT00012142Phase 2
• A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney TransplantTerminatedNCT00005113Phase 3
• CCI-779 in Treating Patients With Advanced Solid TumorsCompletedNCT00003712Phase 1
• Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow TransplantWithdrawnNCT00002790Phase 1/2

← mTOR inhibitors overview